
|Articles|July 1, 2007
- Volume 0 0
MYLAN SCORES VICTORY IN PATENT BATTLE
Advertisement
The latest round in the legal battle over the marketing of generic omeprazole delayedrelease capsules has been won by Mylan Laboratories Inc. A district court in New York ruled that Mylan's generic version of Prilosec does not infringe on AstraZeneca's patents for the popular heartburn drug. At the same time, however, the court held that generic omeprazole products made by 2 other companies, Canada's Apotex Inc and Impax Laboratories Inc in California, do infringe on AstraZeneca's patents.
Articles in this issue
almost 19 years ago
pharmacy TECHNOLOGY newsalmost 19 years ago
pharmacy TECHNOLOGY productsalmost 19 years ago
health-systems PRODUCT newsalmost 19 years ago
generic times product newsalmost 19 years ago
can you READ these Rxs?almost 19 years ago
A closer look at new FDA actionsalmost 19 years ago
can you READ these Rxs?almost 19 years ago
compounding HOTLINEalmost 19 years ago
Is There Science in Quality?almost 19 years ago
Vaccines: Are You Protected?Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADA 2026: Optimized Inhaled Insulin Dosing Outperforms Subcutaneous Analogs for Postprandial Glucose in T1D
2
FDA Grants Breakthrough Therapy Designation to Investigational Cannabis-Derived Therapy for Chronic Low Back Pain
3
The Hidden Reimbursement Crisis in Medicare’s Drug Price Negotiation Program
4
ADA 2026: Distinguishing T1D From T2D in Adults: What the Data Tell Us
5






































































































































